Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 787459, 8 pages
Research Article

Fructus Mume Formula in the Treatment of Type 2 Diabetes Mellitus: A Randomized Controlled Pilot Trial

1National Traditional Chinese Medicine Clinical Research Base for Diabetes Mellitus, Teaching Hospital of Chengdu, University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, China
2Department of Endocrinology, Teaching Hospital of Chengdu, University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, China
3College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China
4Central Hospital of Guangyuan City, Guangyuan, Sichuan 628000, China
5Hospital (T.C.M.) Affiliated to Luzhou Medical College, Sichuan 646000, China
6Traditional Chinese Medicine Hospital of Suining City, Sichuan 629000, China
7Southwestern College, 3960 San Felipe Roud Santa Fe, NM 87507, USA

Received 1 November 2012; Revised 11 January 2013; Accepted 3 February 2013

Academic Editor: William Cho

Copyright © 2013 Xiang Tu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. “Fructus Mume or Dark Plum” (pilule form) has been used for many years in Traditional Chinese Medicine (TCM) and may be a valid treatment for type 2 diabetes mellitus (T2DM). Aim. One aspect toward efficacy validation is the evaluation of the blood glucose-lowering effect of Fructus Mume (FM) with T2DM patients in a randomized controlled trial (RCT). Methods. This pilot study uses a RCT procedure to assess efficacy of FM and Metformin. The trial was for 12 weeks, with 80 T2DM subjects. Both groups were standardized in their diet and exercise routine. Comparisons of several variables were analyzed. Results. No significant differences were found between groups in the fasting and postprandial glucose levels although both had significant decreases. The values of glycosylated hemoglobin were significantly reduced in both groups. For patients whose body mass index (BMI) was <23, neither FM nor Metformin had an effect on BMI; for those with a BMI between 23 and 25 or the BMI was >25, both FM and Metformin significantly reduce the BMI. Conclusions. In this pilot study, it was demonstrated that Fructus Mume formula may reduce the levels of blood glucose in patients with type 2 diabetes.